Naturally Splendid Enterprises Ltd. (TSX-V.NSP, OTCQB: NSPDF, Forum) stated this week that it had entered into a Definitive Agreement with Vancouver-based
Biologic Pharmamedical Research to form a joint venture for the purpose of further developing and pursuing phase 2 clinical studies for a potential COVID-19 treatment, utilizing one of Biologic's patented technologies as a candidate.
For the full story and a deeper look into these details, click
here.
The food manufacturing Company’s
phase 2 clinical COVID-19 trial had been approved by Health Canada earlier last month. The national health agency had requested specific protocol details regarding the Clinical Trial Application for Cavaltinib, the target drug of the proposed joint venture with Biologic Pharmaceutical Research, before the Company’s phase 2 COVID-19 trial can begin.
The test looks at “Cytokine storms”, which are a common complication of COVID-19 and other respiratory diseases caused by coronaviruses such as SARS and MERS. Cytokines are small proteins released by many different cells in the body, including those of the immune system where they coordinate the immune and inflammatory response against infection or other triggers. Cavaltinib has been shown to inhibit these cytokines.
FULL DISCLOSURE: Naturally Splendid Enterprises Ltd. is a client of Stockhouse Publishing.